Gapping up
In reaction to earnings/guidance:
- TCOM +15.6%, RCM +3.3%, SNX +1.6%
Other news:
- KZR +92% (announces positive topline results from the MISSION Phase 2 trial)
- STRO +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
- CRNT +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
- APYX +8% (announced the receipt of 510(k) clearance for the use of the Renuvion Dermal handpiece for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides limited to patients with Fitzpatrick skin types I II or III)
- VLDR +7.1% (announced a multi-year agreement for its lidar sensors with Boston Dynamics)
- VG +6.4% (Ericsson (ERIC) provides update on its acquisition of Vonage)
- ROIV +6.4% (Roivant Sciences and Pfizer (PFE) unveil Priovant Therapeutics and ongoing registrational studies for oral brepocitinib; also reported earnings)
- EIGR +5% (announces results from multiple presentations)
- IDYA +5% (reports development candidate nomination of a potential first-in-class Pol Theta Helicase inhibitor in collaboration with GSK)
- IVR +4.9% (reduces leverage and rotates Agency RMBS portfolio into higher coupons)
- PLTK +4.9% (Joffre Capital aiming to purchase majority stake in PLTK according to Axios)
- SAVE +4.1% (JBLU increases offer to acquire SAVE; TIG Advisors sends letter to SAVE Board regarding its intention to vote "against" proposed merger with Frontier Group Holdings)
- OXY +4% (10% owner Berkshire Hathaway (Warren Buffett) disclosed the purchase of ~794K shares worth ~$44 mln (transaction date 6/23) )
- ULCC +3% (JBLU increases offer to acquire SAVE)
- EPIX +3% (presents clinical update on EPI-7386)
- MS +2.9% (discusses stress test results to increase dividend and announces $20 bln share buyback plan)
- LOVE +2.6% (Lovesac and Joybird resolve patent litigation)
- NLIT +2.6% (reschedules Special Meeting to approve acquisition)
- TFC +2.5% (discusses stress test results to increase dividend by 8%)
- GFF +2.4% (declares special cash dividend of $2/sh)
- ESTE +2.2% (announces northern Delaware basin asset acquisition for ~$627 million)
- AVNW +1.9% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
- GES +1.8% (completes previously disclosed $175 mln ASR program)
- GS +1.8% (discusses stress test results to increase dividend by 25%)
- CFG +1.3% (discusses stress test results increases share repurchase authorization to $1 bln; will consider dividend increase)
- COF +1.3% (discusses stress test results SCB is 3.1%)
- C +1.3% (discusses stress test results intends to maintain current dividend)
- SDGR +1.3% (FDA cleared its investigational new drug application for its MALT1 inhibitor SGR-1505)
- BAC +1.2% (discusses stress test results to increase dividend by 5%)
- JPM +1.2% (discusses stress test results intends to maintain current dividend)
- HPE +1.2% (announces a new partner program)
- BLNK +1.2% (Trilantic Capital Partners discloses 5.7% passive stake)
- WFC +1% (discusses stress test results to increase dividend by 20%)
- FITB +1% (discusses stress test results to recommend to board to increase dividend)
- LE +1% (announces $50 million share repurchase authorization)
Analyst comments:
- FTNT +2.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)